UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 
 
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
 
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
 
Date of Report (Date of earliest event reported):  March 31, 2011
 
 
TIENS BIOTECH GROUP (USA), INC.
 
 
(Exact name of registrant as specified in its charter)
 
         
Delaware  
 
001-32477
 
75-2926439
(State or other jurisdiction  
 
(Commission File Number)  
 
(I.R.S. Employer  
of incorporation)  
     
Identification Number)  

 
No. 17, Xinyuan Rd., Wuqing New Tech Industrial Park, Tianjin, China 301700
 
 
(Address of principal executive offices)
 
 
Registrant’s telephone number, including area code: (011) 86-22-8213-7914
 
 
_______________________________________________________
 
 
(Former name or former address, if changed since last report.)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):
 
 
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
Soliciting materials pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 
 
1
 
 
Item 2.02  Results of Operations and Financial Condition.
 
On March 31, 2011, Tiens Biotech Group (USA), Inc. issued a press release announcing its financial results for the fiscal year ended December 31, 2010.  The full text of the press release is set forth in Exhibit 99.1 attached hereto.
 
Item 9.01  Financial Statements and Exhibits.
 
(d)            Exhibits .
 
Exhibit Number
Description
99.1
Press Release, dated March 31, 2011.

 
 
 
 
2
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
  TIENS BIOTECH GROUP (USA), INC.
   
 Date:  March 31, 2011       By:          /s/ Jinyuan Li
  Name:   Jinyuan Li
  Title:     Chief Executive Officer
 

 
 

 
                                                     
 
3
 

Exhibits
 

Exhibit Number
Description
99.1
Press Release, dated March 31, 2011.
 
 

 
 
4
 
Tiens Biotech GR Usa (AMEX:TBV)
Historical Stock Chart
Von Okt 2024 bis Nov 2024 Click Here for more Tiens Biotech GR Usa Charts.
Tiens Biotech GR Usa (AMEX:TBV)
Historical Stock Chart
Von Nov 2023 bis Nov 2024 Click Here for more Tiens Biotech GR Usa Charts.